Search

Your search keyword '"Amsler, Emmanuelle"' showing total 171 results
Start Over Author "Amsler, Emmanuelle"
171 results on '"Amsler, Emmanuelle"'

1. Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study

Author

Bocquel, Sarah, Soria, Angèle, Raison-Peyron, Nadia, Badaoui, Antoine, Marcant, Pierre, Bara, Corina, Giordano-Labadie, Françoise, Amsler, Emmanuelle, Milpied, Brigitte, Delaunay, Juliette, Darrigade, Anne-Sophie, Pralong, Pauline, Boulard, Claire, Ferrier Le Bouedec, Marie-Christine, Tauber, Marie, Pasteur, Justine, Valois, Aude, Le Thuaut, Aurélie, Crépy, Marie-Noëlle, and Bernier, Claire

Published
2024
Full Text
View/download PDF

2. In Situ Patch Test and Repeated Open Application Test for Fixed Drug Eruption: A Multicenter Study

Author

Traineau, Hélène, Milpied, Brigitte, Soria, Angèle, Assier, Haudrey, Tetart, Florence, Bernier, Claire, Le Bouëdec, Marie-Christine Ferrier, Gener, Gwendeline, Kurihara, Flore, Bauvin, Olivia, Delauney, Juliette, Amsler, Emmanuelle, Bara, Corina, Pelletier, Fabien, Valois, Aude, Castelain, Florence, de Risi Pugliese, Tullia, Hamelin, Aurore, and Barbaud, Annick

Published
2024
Full Text
View/download PDF

3. Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study

Author

Litovsky, Julie, Hacard, Florence, Tétart, Florence, Boccon-Gibod, Isabelle, Soria, Angèle, Staumont-Sallé, Delphine, Doutre, Marie-Sylvie, Amsler, Emmanuelle, Mansard, Catherine, Dezoteux, Frédéric, Darrigade, Anne-Sophie, Milpied, Brigitte, Bernier, Claire, Perrot, Jean-Luc, Raison-Peyron, Nadia, Paryl, Marie, Droitcourt, Catherine, Demoly, Pascal, Grosjean, Julien, Mura, Thibault, and Du-Thanh, Aurélie

Published
2023
Full Text
View/download PDF

6. Cholinergic pruritus treated with omalizumab: Seven cases

Author

Bréhon, Alice, primary, Hamelin, Aurore, additional, Cariou, Claire, additional, Senet, Patricia, additional, Sonigo, Gabrielle, additional, De Risi, Tullia, additional, Barbaud, Annick, additional, Amsler, Emmanuelle, additional, and Soria, Angèle, additional

Published
2024
Full Text
View/download PDF

10. Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study

Author

Bocquel, Sarah, primary, Soria, Angèle, additional, Raison-Peyron, Nadia, additional, Badaoui, Antoine, additional, Marcant, Pierre, additional, Bara, Corina, additional, Giordano-Labadie, Françoise, additional, Amsler, Emmanuelle, additional, Milpied, Brigitte, additional, Delaunay, Juliette, additional, Darrigade, Anne-Sophie, additional, Pralong, Pauline, additional, Boulard, Claire, additional, Ferrier Le Bouedec, Marie-Christine, additional, Tauber, Marie, additional, Pasteur, Justine, additional, Valois, Aude, additional, Le Thuaut, Aurélie, additional, Crépy, Marie-Noëlle, additional, and Bernier, Claire, additional

Published
2023
Full Text
View/download PDF

11. In SituPatch Test and Repeated Open Application Test for Fixed Drug Eruption: A Multicenter Study

Author

Traineau, Hélène, Milpied, Brigitte, Soria, Angèle, Assier, Haudrey, Tetart, Florence, Bernier, Claire, Le Bouëdec, Marie-Christine Ferrier, Gener, Gwendeline, Kurihara, Flore, Bauvin, Olivia, Delauney, Juliette, Amsler, Emmanuelle, Bara, Corina, Pelletier, Fabien, Valois, Aude, Castelain, Florence, de Risi Pugliese, Tullia, Hamelin, Aurore, and Barbaud, Annick

Abstract

Few studies have evaluated allergy workup in fixed drug eruption (FDE) in a large population.

Published
2024
Full Text
View/download PDF

12. Bullous presentation of demodicosis in a young immunocompetent patient.

Author

Tzoumpa, Sofia, Brun, Sophie, Amsler, Emmanuelle, Izri, Arezki, Akhoundi, Mohammad, Caux, Frédéric, Prost‐Squarcioni, Catherine, and Le Roux‐Villet, Christelle

Subjects
SCABIES, IMMUNOCOMPROMISED patients, DEMODEX, MITES, IVERMECTIN, METRONIDAZOLE
Abstract

This article discusses a case of bullous demodicosis, a skin condition caused by the excessive proliferation of Demodex mites. The patient, a 30-year-old Caucasian woman, experienced non-pruritic blisters around her mouth for four years. Despite various treatments, including antiparasitic drugs, the condition persisted. Eventually, weekly doses of oral ivermectin and topical metronidazole led to a complete remission. This case is unusual because bullous demodicosis is typically seen in immunocompromised individuals, and further research is needed to understand the factors influencing the mites' proliferation and effective treatment options. [Extracted from the article]

Published
2024
Full Text
View/download PDF

13. Allergic contact dermatitis from essential oil in consumer products: Mode of uses and value of patch tests with an essential oil series. Results of a French study of the DAG (Dermato‐Allergology group of the French Society of Dermatology).

Author

Barbaud, Annick, Kurihara, Flore, Raison‐Peyron, Nadia, Milpied, Brigitte, Valois, Aude, Assier, Haudrey, Morice, Cécile, Manciet, Jean Romain, Gener, Gwendeline, Giordano‐Labadie, Françoise, Marcant, Pierre, Bernier, Claire, Amsler, Emmanuelle, Crepy, Marie Noelle, Tetart, Florence, Soria, Angèle, and le Bouëdec, Marie‐Christine Ferrier

Subjects
ESSENTIAL oils, TEA tree oil, CONSUMER goods, CONTACT dermatitis, ECZEMA
Abstract

Objective: To analyse the clinical characteristics and sensitivity of an essential oil patch test series (EOS) in patients sensitized to their own essential oils (EOs). Method: We analysed the clinical data and patch test results obtained with the European baseline series (BSE) and an EOS, as well as the mode of use of EOs, through a questionnaire included in the patient file. Results: The study included 42 patients (79% women, average age 50 years) with allergic contact dermatitis (ACD), 8 patients required hospitalization. All patients were sensitized to the EO they used, primarily lavender (Lavandula augustifolia, 8000‐28‐0), tea tree (Melaleuca alternifolia leaf oil, 68647‐73‐4), ravintsara (Cinnamomum camphora oil, 92201‐50‐8), and 2 cases were attributed to helichrysum (helichrysum italicum flower absolute, 90045‐56‐0). 71% had positive patch tests to fragrance mix I or II, 9 only to the EOS and 4 only with their personal EO. Interestingly, 40% of patients did not spontaneously mention the use of EOs, and only 33% received advice on their use at the time of purchase. Conclusion: Patch tests with the BSE, limonene and linalool HP, and oxidized tea tree oil is sufficient to detect most EO‐sensitized patients. The most important is to test the patient's own used EOs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Systemic inflammatory trunk recurrent acute macular eruption ( SITRAME ): A new auto‐inflammatory syndrome in adult?

Author

Soria, Angèle, primary, Amsler, Emmanuelle, additional, Garel, Bethsabée, additional, Moguelet, Philippe, additional, Tieulié, Nathalie, additional, Cordoliani, Florence, additional, Guichard, Isabelle, additional, Mahé, Antoine, additional, Grateau, Gilles, additional, Boursier, Guilaine, additional, and Georgin‐Lavialle, Sophie, additional

Published
2022
Full Text
View/download PDF

15. Chemical characterization of inks in skin reactions to tattoo

Author

Colboc, Hester, primary, Bazin, Dominique, additional, Reguer, Solenn, additional, Lucas, Ivan T., additional, Moguelet, Philippe, additional, Amode, Reyhan, additional, Jouanneau, Chantal, additional, Soria, Angèle, additional, Chasset, François, additional, Amsler, Emmanuelle, additional, Pecquet, Catherine, additional, Aractingi, Sélim, additional, Bellot-Gurlet, Ludovic, additional, Deschamps, Lydia, additional, Descamps, Vincent, additional, and Kluger, Nicolas, additional

Published
2022
Full Text
View/download PDF

17. Discrepancies in the management of acquired cold contact urticaria: Results of a French-speaking urticaria experts questionnaire survey

Author

Du-Thanh, Aurélie, primary, Soria, Angèle, additional, Amsler, Emmanuelle, additional, Badaoui, Antoine, additional, Doutre, Marie-Sylvie, additional, Gabison, Germaine, additional, Bernier, Claire, additional, Staumont-Sallé, Delphine, additional, Hacard, Florence, additional, Castelain, Florence, additional, Darrigade, Anne-Sophie, additional, Tapsoba, Gilbert Patrice ML, additional, Sarre, Marie-Elodie, additional, Mathelier-Fusade, Pascale, additional, Delaunay, Juliette, additional, Pralong, Pauline, additional, Barbaud, Annick, additional, Dezoteux, Frédéric, additional, Trémeau-Martinage, Catherine, additional, Bachtarzi, Zhary, additional, and Augey, Frédéric, additional

Published
2022
Full Text
View/download PDF

20. Airborne allergic contact dermatitis caused by isothiazolinones in water‐based paints: a retrospective study of 44 cases

Author

Amsler, Emmanuelle, Aerts, Olivier, Raison‐Peyron, Nadia, Debons, Michèle, Milpied, Brigitte, Giordano‐Labadie, Françoise, Waton, Julie, Ferrier‐Le Bouëdec, Marie C., Lartigau, Isabelle, Pecquet, Catherine, Assier, Haudrey, Avenel‐Audran, Martine, Bernier, Claire, Castelain, Florence, Collet, Evelyne, Crépy, Marie‐Noëlle, Genillier, Nathalie, Girardin, Pascal, Pralong, Pauline, Tetart, Florence, Vital‐Durand, Dominique, Soria, Angele, and Barbaud, Annick

Published
2017
Full Text
View/download PDF

23. Allergic contact dermatitis caused by PEG‐22 and PEG‐45 dodecyl glycol copolymers in two skin‐repairing creams.

Author

Brehon, Alice, Soria, Angèle, Barbaud, Annick, and Amsler, Emmanuelle

Subjects
ETHYLENE glycol, CONTACT dermatitis, COPOLYMERS, GLYCOLS, ECZEMA, BENZYL alcohol
Abstract

Keywords: allergic contact dermatitis; CAS no. 78336-31-9; case report; copolymers; cosmetic products; PEG-22/dodecyl glycol copolymer; PEG-45/dodecyl glycol copolymer EN allergic contact dermatitis CAS no. 78336-31-9 case report copolymers cosmetic products PEG-22/dodecyl glycol copolymer PEG-45/dodecyl glycol copolymer 213 215 3 08/04/23 20230901 NES 230901 We report a case of allergic contact dermatitis (ACD) caused by PEG-22/dodecyl glycol copolymer and PEG-45/dodecyl glycol copolymer contained in two different "skin-repairing" creams. Allergic contact dermatitis, CAS no. 78336-31-9, case report, copolymers, cosmetic products, PEG-22/dodecyl glycol copolymer, PEG-45/dodecyl glycol copolymer Allergic contact dermatitis caused by PEG-22 and PEG-45 dodecyl glycol copolymers in two skin-repairing creams. [Extracted from the article]

Published
2023
Full Text
View/download PDF

24. Bilan allergologique des érythèmes pigmentés fixes : une étude multicentrique FISARD

Author

Traineau, Hélène, primary, Milpied, Brigitte, additional, Soria, Angèle, additional, Assier, Haudrey, additional, Bernier, Claire, additional, Gener, Gwendeline, additional, Tetart, Florence, additional, Kurihara, Flore, additional, Amsler, Emmanuelle, additional, Ferrier Le Bouedec, Marie Christine, additional, Bara, Corina, additional, De Risi, Tullia, additional, Castelain, Florence, additional, Pelletier, Fabien, additional, Delauney, Juliette, additional, Bauvin, Olivia, additional, Valois, Aude, additional, Hamelin, Aurore, additional, and Barbaud, Annick, additional

Published
2021
Full Text
View/download PDF

25. Durée optimale du ROAT, expérience du groupe dermato allergologie de la Société française de dermatologie

Author

Amsler, Emmanuelle, primary, Assier, Haudrey, additional, Soria, Angele, additional, Bara, Corina, additional, Bouëdec, Marie Christine Ferrier le, additional, Barbaud, Annick, additional, Milpied, Brigitte, additional, Giordano-Labadie, Françoise, additional, Pasteur, Justine, additional, Badaoui, Antoine, additional, Hamelin, Aurore, additional, kurihara, Flore, additional, Castagna, Julie, additional, Boulard, Claire, additional, Bernier, Claire, additional, Leleu, Camille, additional, Marcant, Pierre, additional, Crepy, Marie Noelle, additional, Valois, Aude, additional, Castelain, Florence, additional, Tetart, Florence, additional, and Raison-Peyron, Nadia, additional

Published
2021
Full Text
View/download PDF

27. Eczéma chronique des mains (ECM) chez les patients porteurs de gants

Author

Clément, Aude, primary, Ferrier le Bouëdec, Marie-Christine, additional, Raison Peyron, Nadia, additional, Tétart, Florence, additional, Marcant, Pierre, additional, Pralong, Pauline, additional, Valois, Aude, additional, Pasteur, Justine, additional, Assier, Haudrey, additional, Bernier, Claire, additional, Le Cam, Marie-Thérèse, additional, Nosbaum, Audrey, additional, Crépy, Marie-Noëlle, additional, Giordano Labadie, Françoise, additional, Morice, Cécile, additional, Leleu, Camille, additional, Milpied, Brigitte, additional, Darrigade, Anne-Sophie, additional, Delaunay, Juliette, additional, Barbaud, Annick, additional, Castelain, Florence, additional, Collet, Evelyne, additional, and Amsler, Emmanuelle, additional

Published
2021
Full Text
View/download PDF

28. Explorations allergologiques des nécrolyses épidermiques : étude multicentrique rétrospective

Author

Roux, Camille, primary, Said, Benoît Ben, additional, Milpied, Brigitte, additional, Bernier, Claire, additional, Staumont, Delphine, additional, Dezoteux, Frédéric, additional, Soria, Angèle, additional, Barbaud, Annick, additional, Amsler, Emmanuelle, additional, Tétart, Florence, additional, Bellon, Nathalia, additional, Lebrun-Vignes, Bénédicte, additional, Gener, Gwendeline, additional, Oro, Saskia, additional, and Assier, Haudrey, additional

Published
2021
Full Text
View/download PDF

32. What is the optimal duration for a ROAT? The experience of the French Dermatology and Allergology group (DAG).

Author

Amsler, Emmanuelle, Assier, Haudrey, Soria, Angèle, Bara, Corina, Ferrier le Bouëdec, Marie Christine, Barbaud, Annick, Milpied, Brigitte, Giordano‐Labadie, Françoise, Pasteur, Justine, Badaoui, Antoine, Valois, Aude, Castelain, Florence, Kurihara, Flore, Castagna, Julie, Boulard, Claire, Bernier, Claire, Leleu, Camille, Marcant, Pierre, Crépy, Marie Noelle, and Tetart, Florence

Subjects
*CONTACT dermatitis, *DERMATOLOGY, *SKIN tests, *LONGITUDINAL method
Abstract

Background and Objectives: The repeated open application test (ROAT) is an adjuvant investigation measure to patch testing in the diagnosis of allergic contact dermatitis. ESCD recommends a 15 days duration but its overall duration varies according to publications and patients hardly adhere to prolonged ROAT duration beyond 1 week. Materials and Methods: The Dermatology and Allergy Group of the French Society of Dermatology performed a prospective study with the aim of determining the best duration for the ROAT. Results: A total of 328 ROAT results were collected for topical products, including cosmetics (60%) and topical medications (31.1%). Fifty‐nine (18%) ROATs were positive, and 16 (5%) were doubtful. All the positive ROATs occurred within 10 days, with a median time to positivity of 3 days. Conclusion: According to our results, a minimum duration of 10 days is necessary to achieve a positive ROAT to a topical product. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Clinical Communications Symmetrical drug-related intertriginous and flexural exanthema: A little-known drug allergy

Author

Risi-Pugliese, Tullia de, Barailler, Héloïse, Hamelin, Aurore, Amsler, Emmanuelle, Gaouar, Hafida, Kurihara, Flore, Jullie, Marie Laure, Merrill, Eric Dean, Barbaud, Annick, Moguelet, Philippe, Milpied-Homsi, Brigitte, Soria, Angèle, Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Hôpital Saint-André, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], University of California [San Francisco] (UCSF), University of California, Service d’Anatomopathologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et de Maladies Infectieuses (CIMI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; Symmetrical drug-related intertriginous and flexural exanthema is a flexural eruption that occurs within a few days of drug exposure. Antibiotics and iodinated contrast agents are the most frequent triggers. Skin testing has low sensitivity. Rechallenge identifies the culprit drug without serious manifestations. The symmetrical drug-related intertriginous and flexural ex-anthema (SDRIFE) is a delayed flexural exanthema induced by a systemic drug without previous cutaneous sensitization, typically presenting as "a sharply defined symmetrical erythema of the gluteal area and in the flexural or intertriginous folds without systemic symptoms and signs." 1 SDRIFE clinically resembles Baboon syndrome (BS); however, in BS, patients develop the exanthem after systemic exposure to an allergen to which they have been previously topically sensitized. 2 We retrospectively reviewed records from 2 French dermatology departments between 2006 and 2018 for adults with SDRIFE as defined by Häusermann et al 1 : (1) exposure to systemically administered drug either following the first or subsequent dose, (2) sharply demarcated erythema of the gluteal and/or inguinal area, (3) involvement of at least 1 other flexural localization, (4) symmetry of affected area, and (5) absence of systemic symptoms and signs. Twelve patients were excluded because of previous topical sensitization to the allergen (BS, n ¼ 2), diffuse maculopapular rash (MPR) with flexural reinforcement (n ¼ 7), other causes of flexural rash, for example, acute generalized exanthematous pustulosis (AGEP), toxic er-ythema due to chemotherapy (TEC) based on clinical and histological findings (n ¼ 2), and flexural erythema thought to be drug-induced but without relapse after reexposure (n ¼ 1). Patch tests (PTs) (IQ ultrachambers, Chemotechnique Diagnostics, Velinge, Sweden), skin prick tests (SPTs), and intradermal tests (IDTs) with delayed readings were performed following European guidelines 3 (Table I). We further reviewed all published cases of SDRIFE since Häusermann et al's publication (2004-2018). Eighteen patients were included, 10 females and 8 males, with mean and median ages of 57 years (range, 33-83 years). Erythematous patches or plaques affecting a mean of 5 (range, 2-7) large or small skin folds (especially inguinal, gluteal, axillary, and mammary) (Figure 1, Table I) were observed. Four patients had localized skin vesicles or bullae and 1 (no. 16) had mucosal involvement. The eruption occurred shortly after drug exposure (median, 22 hours; mean, 34; range, 0.5-120). The causative drug was discontinued immediately in all patients, 10 were treated with topical steroids, and resolution of lesions was observed within a median of 4 days (mean, 6.2; range, 1-18). Lymphopenia was found in 6 of 12 patients (50%; range, 350-1400/mm 3), not explained by a distinct underlying condition. The most frequent histological pattern, found in 5 of 11 patients who had a skin biopsy, was subepidermal edema with a polymorphous perivascular and interstitial infiltrate of neutro-phils, eosinophils, and lymphocytes in the upper dermis. Four patients had a spongiotic and/or lichenoid pattern on skin biopsy and 2 had a nonspecific scant lymphocytic superficial peri-vascular infiltrate. There was no obvious relationship between histology and the clinical presentation and severity of the rash or timing of skin biopsy. The suspected drug was an antibiotic in 10 of 18 cases (56%), including amoxicillin AE clavulanate in 4 (22%), a iodinated contrast agent (ICA) in 5 of 18 (28%), an analgesic in 2 of 18, and fluconazole in 1 of 18 (Table I). Fourteen patients had PT, 12 had SPT, and 11 IDT with delayed readings. Testing was performed within 1 month to 9 years of the original reaction, and most patients (13 of 16) were tested within 1 year of the reaction. Positive skin test results were obtained only in 5 patients, all with antibiotics: PT in 3 of 14 cases (21%): 1 with amoxicillin-clavulanate and 2 with pristinamycin; IDT in 2 of 11 cases (18%) with amoxicillin AE clavulanate. Skin test results remained negative in patient number 2 who also had a SDRIFE due to amoxicillin confirmed by rechallenge test (RT). Results of all skin tests performed with ICAs (PT n ¼ 3, SPT and IDT n ¼ 5) were negative. The result of RT with the suspected causative drug, performed in 9 patients with negative skin test results, was always positive, without severe cutaneous or systemic manifestations. There was no obvious relationship between clinical presentation and positivity of skin test results. The median time for SDRIFE recurrence after reexposure to the drug (induced by RT [n ¼ 9] or skin tests [n ¼ 1]) was 12 hours (mean, 15 hours; range 2.5-30), shorter than during the first episode. SDRIFE is thought to involve a type IV delayed-hypersensitivity immune response, because it occurs within a few hours to a few days after drug exposure, and there is evidence for a T-cellemediated reaction, 1,4 though the precise physiopa-thology is not known. Antibiotics are common triggering agents in the literature (60% in Häusermann et al's 1 review, 33% in our literature review [2004-2018], n ¼ 51 [see Tables E1 and E2 in this article's Online Repository at www.jaci-inpractice.org]), especially beta-lactams (55% in Hausermann et al's review and 23% in our review), but only 5 cases of SDRIFE due to ICAs were reported. 5 In previously published cases, skin test results were positive more frequently than in our study, 40% of PTs, 11% of SPTs, and 70% of IDTs, for various drugs (antibiotics and others), possibly due to a publication bias. Different methods for identifying the culprit drug might be necessary in SDRIFE. Skin testing on affected sites is one option; however, 3185

Published
2020

41. Management of urticaria by French specialists compared to international guideline recommendations

Author

Berard, F., Viguier, M., Lefevre, S., Vigan, M., Barzegar, C., Boussaid, R., Hacard, F., Gabison, G., Staumont, D., Marmion, N., Pouplard, C., Delaunay, J., Badaoui, A., Nosbaum, A., Pralong, P., Castelain, F., Bouillet, L., Sarre, M.E., Vermeulen, C., Tetart, F., Bachtarzi, Z., Doutre, M.S., Martinache, C., Bara, C., Augey, F., Boccon Gibod, I., Nicolas, J.F., Maatouk, I., Mathelier Fusade, P., Soutou, B., Goujon Henry, C., Hoarau, C., Crépy, M.N., Bernier, C., Cambazard, F., Guinepain, M.T., Amsler, Emmanuelle, Du Thanh, Aurelie, and Soria, Angèle

Published
2020
Full Text
View/download PDF

43. Management of urticaria by French specialists compared to international guideline recommendations

Author

Amsler, Emmanuelle, primary, Du Thanh, Aurelie, additional, Soria, Angèle, additional, Berard, F., additional, Viguier, M., additional, Lefevre, S., additional, Vigan, M., additional, Barzegar, C., additional, Boussaid, R., additional, Hacard, F., additional, Gabison, G., additional, Staumont, D., additional, Marmion, N., additional, Pouplard, C., additional, Delaunay, J., additional, Badaoui, A., additional, Nosbaum, A., additional, Pralong, P., additional, Castelain, F., additional, Bouillet, L., additional, Sarre, M.E., additional, Vermeulen, C., additional, Tetart, F., additional, Bachtarzi, Z., additional, Doutre, M.S., additional, Martinache, C., additional, Bara, C., additional, Augey, F., additional, Boccon Gibod, I., additional, Nicolas, J.F., additional, Maatouk, I., additional, Mathelier Fusade, P., additional, Soutou, B., additional, Goujon Henry, C., additional, Hoarau, C., additional, Crépy, M.N., additional, Bernier, C., additional, Cambazard, F., additional, and Guinepain, M.T., additional

Published
2020
Full Text
View/download PDF

44. Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: A randomized, controlled trial

Author

Leducq, Sophie, primary, Samimi, Mahtab, additional, Bernier, Claire, additional, Soria, Angèle, additional, Amsler, Emmanuelle, additional, Staumont-Sallé, Delphine, additional, Gabison, Germaine, additional, Chosidow, Olivier, additional, Bénéton, Nathalie, additional, Bara, Corina, additional, Grange-Prunier, Anne, additional, Wierzbicka-Hainaut, Ewa, additional, Brenaut, Emilie, additional, Droitcourt, Catherine, additional, Raison-Peyron, Nathalie, additional, Bourgoin, Hélène, additional, Cornillier, Hélène, additional, Machet, Laurent, additional, Giraudeau, Bruno, additional, Caille, Agnès, additional, and Maruani, Annabel, additional

Published
2020
Full Text
View/download PDF

47. Vaccination-induced cutaneous pseudolymphoma

Author

Maubec, Eve, Pinquier, Laure, Viguier, Manuelle, Caux, Frédéric, Amsler, Emmanuelle, Aractingi, Sélim, Chafi, Hafid, Janin, Anne, Cayuela, Jean-Michel, Dubertret, Louis, Authier, François-Jérôme, and Bachelez, Hervé

Published
2005
Full Text
View/download PDF

48. Evaluation of a low-dose methotrexate added to h1-antihistamines regimen for severe chronic spontaneous urticaria: a phase III, randomized, placebo-controlled trial

Author

Leducq, Sophie, Samimi, Mahtab, Bernier, Claire, Soria, Angele, Amsler, Emmanuelle, Staumont-Sallé, Delphine, Gabison, Germaine, Chosidow, Olivier, Beneton, Nathalie, Bara, Corina, Grange-Prunier, Anne, Wierzbicka-Hainaut, Ewa, Brenaut, Emilie, Droitcourt, Catherine, Raison-Peyron, Nathalie, Giraudeau, Bruno, Bourgoin, Helene, Cornillier, Hélène, Machet, Laurent, Caille, Agnès, Maruani, Annabel, Service de dermatologie, Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Infectiologie et Santé Publique (UMR ISP), Institut National de la Recherche Agronomique (INRA)-Université de Tours, Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Lille (CHU de Lille), Centre Hospitalier Universitaire Henri Mondor, Service de Dermatologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Reims (CHU Reims), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Augustin Morvan, CHU Pontchaillou [Rennes], Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU de Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Institut National de la Recherche Agronomique (INRA)-Université de Tours (UT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and ProdInra, Migration

Subjects
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience; Introduction: H1-antihistamines (anti-H1) are the first-line treatment for chronic spontaneous urticaria (CSU). Immunosuppressive drugs may be proposed in case of incomplete improvement of CSU. Objective: To evaluate the efficacy of a low-dose methotrexate added to H1-antihistamines regimen for CSU resistant to anti-H1 treatment, compared with anti-H1 monotherapy in a randomized, placebo-controlled trial. Materials and Methods: Patients with CSU resistant to at least a 3 month-period of anti-H1 were randomly assigned to receive either low-dose methotrexate (0.2 mg/kg/week) or placebo in addition to anti-H1. Primary outcome was the proportion of patient with complete remission of CSU after 18 weeks (W18), defined as no urticarial lesion within the previous 30 days. Intention to treat analyses were performed (failure was considered when data on primary outcome were missing). Results: From November 2011 to May 2016, 75 patients were randomized: 39 were allocated to methotrexate and 36 to placebo. In the intention to treat population, 3 patients in the methotrexate group (7.9%) and 0 patient in the placebo group (0.0%) had a complete remission at W18 (difference, 7.9 percentage points, [95% confidence interval (CI) -4.0 to 20.8], p=0.24). Eleven patients in the methotrexate group (29.0%) and 6 patients in the placebo group (18.8%) had less than 7 days with urticarial lesions within the 30 days before W18 (difference, 10.2 percentage points, [95% CI -10.2 to 28.8], p=0.40). Clinical adverse events occurred in 56.4% of patients in the methotrexate group and 50.0% in the placebo group (p=0.58), mostly gastrointestinal symptoms. Biological adverse events occurred in 59.0% of patients in the methotrexate group and 30.6% in the placebo group (p=0.01), mainly increased blood level of transaminases. Conclusions: We did not evidence any superiority of a low dose methotrexate added to anti-H1, compared with anti-H1 monotherapy, for patients with chronic spontaneous urticarial.

Published
2019

50. Paradoxical urticaria to H1‐antihistamines.

Author

Soria, Angèle, Kurihara, Flore, Amsler, Emmanuelle, Bréhon, Alice, Autegarden, Jean Eric, and Barbaud, Annick

Subjects
*INFORMED consent (Medical law), *SKIN tests, *ALLERGIC conjunctivitis, *DRUG allergy, *HISTAMINE receptors, *URTICARIA
Abstract

This document is a letter to the editor discussing paradoxical urticaria reactions to H1-antihistamines. The authors report on nine patients with paradoxical urticaria who experienced hives from different classes of H1-antihistamines. The cause of this reaction is still unclear, but it may be related to mast cell degranulation or disruption of the arachidonic acid metabolism pathway. Physicians should be aware of this diagnosis and perform an allergy work-up, including skin testing, in patients suspected of having paradoxical urticaria. The letter includes a table summarizing the clinical characteristics and allergy work-up of the identified cases. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results